« Back To Business Top

print

Daiichi Sankyo to acquire German biomedical firm

Thursday 22nd May, 05:04 AM JST

TOKYO —

Daiichi Sankyo Co said Wednesday it has agreed to acquire German biomedical firm U3 Pharma AG for 150 million euros. U3 Pharma focuses on research into antibodies for the treatment of cancer.

“Our acquisition of U3 Pharma is an ideal strategic fit for our oncology portfolio,” said Takashi Shoda, president and chief executive of the major Japanese drug maker, in a statement.

JCN

0 Comments

Register or login to add a comment!